Gilead Sciences

Gilead Sciences

Yahoo Finance • 2 days ago

Gilead Sciences Has Snapped Out of Its Slump -- and 1 Catalyst Is Doing Most of the Heavy Lifting

After months of sideways price action, Gilead Sciences (NASDAQ: GILD) has started zooming higher. This comes on the heels of the pharmaceutical company's latest quarterly earnings release. Trading around $130 per share ahead of earnings,... Full story

Yahoo Finance • 5 days ago

Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise?

Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to approximately $7.8 billion. The performance was primarily driven by continued growth across its HIV franchise, inc... Full story

Yahoo Finance • 5 days ago

Gilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?

Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease. Total revenue increased 10% year over year to approximat... Full story

Yahoo Finance • 5 days ago

Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?

The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday's blockbusters, and whether Gilead Sciences, Inc. (NASDAQ:GILD) can become more than an HIV company. Pfizer's (NYSE:PFE) newer medicines are gaining traction... Full story

Yahoo Finance • 7 days ago

Making Drugs With AI: Biopharma Giants Gear Up For New Arena

The biggest names behind biotech stocks are investing richly in artificial intelligence with the goal of speeding up drug development. Continue Reading... Full story

Yahoo Finance • 9 days ago

Worried About a Market Crash? These 3 Stocks Beat the S&P 500 in 2008 and 2022

The stock market may be on borrowed time these days. It's been doing well, perhaps too well, given the state of the economy. Many people are struggling due to inflation and cutting back on expenses. Although the S&P 500 reaching record lev... Full story

Yahoo Finance • 9 days ago

Trump expected to nominate White House aide Heidi Overton as FDA commissioner

[FDA Headquarters] President Donald Trump is expected to tap Heidi Overton, a top aide at the White House’s Domestic Policy Council, to serve as the next commissioner of the Food and Drug Administration, according to multiple media report... Full story

Yahoo Finance • 10 days ago

Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.

Gilead Sciences (NASDAQ: GILD) has shifted from a period of stagnant growth, driven by slowing hepatitis C revenues and declining sales of its COVID-19 therapy Veklury, to a turnaround led by new HIV and oncology drugs. The pharmaceutical... Full story

Yahoo Finance • 11 days ago

Cancer & Antibody Conjugates Patent Landscape Report: Evaluating 3,761 Patent Families, Linker-Payload Technologies, and Strategies of Roche, Daiichi Sankyo, Gilead, and AstraZeneca

Company Logo apid clinical validation of antibody-drug conjugates (ADCs) and renewing interest in targeted radioimmunoconjugates highlighted by commercial momentum and patent consolidation from Roche/Genentech, Daiichi Sankyo, Gilead Scie... Full story

Yahoo Finance • 12 days ago

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings? Over the last six months, Gilead Sciences's shares have sunk to $137.77, producing a disappointing 11.3% loss - a stark contrast to the S&P 500's 13.1% gain. This might have inv... Full story

Yahoo Finance • 14 days ago

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc. (NASDAQ:MGNX)'s proprietary TRIDENT platform. The decision trigge... Full story

Yahoo Finance • 14 days ago

BofA biotech scorecard: Two buys and odd one out

Picture three students turning in exams on the same day, covering the same material. Two walk away with high marks. The third has been raising his grades all semester, yet still gets flagged for summer school. That is roughly the dynamic... Full story

Yahoo Finance • 15 days ago

Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine

Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc. (NASDAQ:GILD), are proving that in modern drug development, the biggest catalyst isn't always competing head-to-head; it is knowing when to join forces. While bot... Full story

Yahoo Finance • 15 days ago

Noteworthy ETF Outflows: TQQQ, ADI, MRVL, GILD

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ProShares UltraPro QQQ (Symbol: TQQQ) where we have detected an approximate $156.7 million dollar outflow --... Full story

Yahoo Finance • 15 days ago

Why Gilead Sciences (GILD) Is Back In The Spotlight

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Gilead Sciences (GILD) is back in focus after announcing a collaboration with Nucleai that applies AI powered tissue a... Full story

Yahoo Finance • 16 days ago

3 Healthcare Stocks with Open Questions

3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only ri... Full story

Yahoo Finance • 17 days ago

The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"

A Milestone 20th Anniversary Edition Recognizing Excellence in Medical Science and Patient Care NEW YORK, Aug. 11, 2026 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life science... Full story

Yahoo Finance • 17 days ago

Non-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific

Company Logo Dublin, Aug. 11, 2026 (GLOBE NEWSWIRE) -- The "Non-Viral Transfection Reagents Market (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User and Geographical Regions-Trends and Forecast Till 2035"... Full story

Yahoo Finance • 20 days ago

Key HIV stat over 70% leaves BofA siding with Gilead

Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading int... Full story

Yahoo Finance • 23 days ago

Gilead Sciences in charts: Q2 base sales jump 10% on HIV, oncology growth despite Veklury drop

[ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha [ ] Seeking Alpha   MORE ON GILEAD SCIENCES * Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript [https://seekingalpha.com/article/4930335-gilead-sci... Full story